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Bacteriodes fragilis and polysaccharide A capsular antigen (PSA) produced by this commensal bacteria can
mediate immune tolerance in the gastrointestinal (GI) tract. When looking for naturally secreted forms of PSA,
Shen et al. (2012) suprisingly found that PSA is packaged in outer membrane vesicles (OMVs), bacterial blebs
with a disreputable past.Polysaccharide A capsular antigen (PSA)
produced by the commensalBacterioides
fragilis has immunomodulatory effects
and treatment with B. fragilis or PSA alone
can induce immune tolerance, a condi-
tion critical to preventing inflammatory
bowel disease (IBD) and Crohn’s disease
(Mazmanian et al., 2008; Round and
Mazmanian, 2010). In this issue, Maz-
manian and colleagues extend these
findings and show that outer membrane
vesicles (OMVs) derived from B. fragilis
are the delivery device by which PSA is
transported to dendritic cells (DCs) to
favorably modulate the immune system
(Shen et al., 2012). They further delineate
the key messengers in the process—
TLR2-mediated OMV-PSA recognition
and Gadd45a signaling in DCs, produc-
tion of the immunoregulatory cytokine
IL-10 by DCs and Tregs (T regulatory
cells), and the consequent prevention of
T helper cell proliferation and production
of inflammatory mediators (Figure 1). The
authors not only demonstrate these
processes using in vitro assays but also
show results using an animal model of
experimental colitis that are impressively
consistent with this pathway.
OMVs are well on their way to becom-
ing widely recognized for being ubiqui-
tously produced by pathogens and
nonpathogens alike (Deatherage and
Cookson, 2012; Kulp and Kuehn, 2010).
However, OMVs have not always enjoyed
serious or benevolent consideration. For
some time they were deemed as products
of bacterial lysis or death. Shortcomings
in mechanistic details have plagued the
OMV field, only now emerging as a bona
fide secretion mechanism (McBroom
et al., 2006). OMV production captures
both the insoluble outermost membrane
and soluble portions of lumenal content;
thus, in the case of Gram-negative392 Cell Host & Microbe 12, October 18, 201bacteria, the vesicles are spherical por-
tions of outer membrane with lumenal
periplasmic content. Additionally, based
on the organisms for which they have
been studied and the molecules they
transport, OMVs are typically considered
virulence factors (Ellis and Kuehn, 2010).
In cases when bacterial toxins are
attached to the outer bacterial mem-
brane, such as for cytolysin A (ClyA) in
uropathogenic Escherichia coli, hemo-
lysin (HlyA) in extraintestinal pathogenic
E. coli, or heat-labile enterotoxin (LT) in
enterotoxigenic E. coli, these toxins are
also associated with the external OMV
surface. Other notable OMVcargo include
peptidoglycan, flagellin, lipopolysaccha-
ride (LPS), and CpG DNA, pathogen-
associated molecular patterns (PAMPs)
that can significantly activate inflam-
matory immune responses. Therefore,
by describing their benefit to the host
in reducing harmful inflammation, Shen
et al. introduce a new paradigm to the
field.
Shen et al. discuss several questions
evoked by their study. Notably, what are
the details of the internal signaling
pathway that result in IL-10 activation
by PSA+ OMVs? They have begun to
address this using microarray results
and identify differences in transcriptional
profiles of specific genes in TLR2+/+
and / bone marrow-derived DCs that
have been activated with either PSA+
OMVs or DPSA OMVs. They also raise
the question of how the signals between
commensals and immune cells as well
as those between immunomodulatory
cells are communicated. They speculate
that OMV-mediated delivery is likely
beneficial for long-distance delivery, a
process discussed in more detail in a
recent review (Kulp and Kuehn, 2010),
and may play a role in host-commensal2 ª2012 Elsevier Inc.communication. Answers regarding the
communication between DCs, Tregs,
and CD4+ Tcells will also further our
understanding of tolerance versus
adaptive immunity. Finally, they question
whether OMV content besides PSA might
contribute to the process.
In the case of beneficial PSA+ OMV
signaling, it will be important to under-
stand why B. fragilis OMVs also harbor
polysaccharide B (PSB) and not poly-
saccharide G (PSG). To date, there are
ever-increasing examples of enriched/
excluded OMV cargo (Kulp and Kuehn,
2010), but little is known about the
genetically controlled mechanics of this
process. Assessing a seemingly basic
question of whether OMVs harbor PSA
on their interior or exterior might begin
the process of understanding the selec-
tivity. Or, perhaps it is something physical
about the type of polysaccharide cargo
that induces OMV production. Data pre-
sented in this study showed no difference
in the amount of OMV production for
PSA+ and DPSA bacteria, demonstrating
that PSA is not responsible. Addressing
these questions will further OMV research
because they address some poorly
understood aspects of OMV-mediated
secretion.
If B. fragilismakes OMVs during normal
growth in a healthy gut, and the gut
houses (at least) thousands of types
of bacteria that likely produce OMVs,
how is the immune system discerning
responses to the large cast of immu-
nomodulatory components associated
with those OMVs? Do DCs, which are
expected to take up OMVs indiscrimin-
ately, only respond to those made by
B. fragilis? In addition to OMV content,
it should also be considered that native
packaging of the cargo matters. For
instance, does a mixture of DPSA OMVs
Figure 1. Model Summarizing the Promotion of Tolerance and the
Suppression of a Damaging Inflammatory Response by B. fragilis
OMVs in the GI Tract
B. fragilis produces polysaccharide A capsular antigen (PSA)-containing
OMVs that are recognized by dendritic cells (DCs) through TLR2. Gadd45a
signaling and IL-10 production in DCs is required to induce T regulatory cell
(Treg) responses, notably IL-10 production, that suppress CD4 T cell-medi-
ated inflammatory responses. Due to these immunmodulatory effects, PSA-
containing OMVs can prevent experimental colitis and thus have therapeutic
potential for inflammatory bowel disease (IBD) and Crohn’s disease. See
text and (Shen et al., 2012) for additional details.
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PSA signal along the same
pathways as PSA+ OMVs?
This is not an idle question,
since it was not the case for
experiments comparing epi-
thelial monolayer production
of the proinflammatory cyto-
kines TNFa and IL-6 in
response to DLT OMVs sup-
plemented with LT versus
LT+ OMVs (Chutkan and
Kuehn, 2011). In other words,
themanner by which bacterial
factors are associated with
OMVs impacts host cell
signaling. In a complex milieu
of OMVs, secreted bacterial
factors, and secreted host
factors, it is not surprising
that the immune system is
sensitive to not only what is
being presented but how it
is being presented.
It should also be mentioned
here that eukaryotic cellsproduce membrane vesicles (MVs) and
exosomes, which are relatives of OMVs
(Deatherage and Cookson, 2012). As
with their bacterial counterparts, these
eukaryote-derived vesicles have been
observed for decades; however, their
mechanism of production and function
are only now being elucidated. Their roles
in intercellular communication and immu-
nobiology show unsurprising parallels
with OMV-mediated signaling.
In sum, Shen et al. have uncovered
the physiological benefit of the OMV-captured capsular material produced
by a commensal gut organism. Recent
discoveries comparing diseased and
healthy microbiome states and the role
of the microbiome in gastrointestinal (GI)
tract development (Chung et al., 2012;
Kau et al., 2011) have raised a multitude
of questions regarding the physical gap
between bacterial symbionts and the
immunology of the GI tract. This study
by the Mazmanian group of how
B. fragilis activates an anti-inflammatory
program in the gut is a successful andCell Host & Microbe 12, October 18,satisfying example of how to
approach the identification
of the molecular basis by
which mammals overcome
this gap. As a bonus, their
findings could generate solu-
tions for individuals suffering
from IBD,Crohn’s, andcolitis.REFERENCES
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